A nurse is reviewing a client's medical history before administering a new prescription for atropine. Which of the following client conditions is contraindicated?

B) Nalbuphine: Nalbuphine is an opioid analgesic that acts on the central nervous system to relieve pain. When administered concurrently with morphine, there is a risk of additive respiratory depression and other opioid-related side effects, such as sedation and hypotension. Therefore, the nurse should clarify the prescription for nalbuphine with the provider to ensure that the combination of opioid medications is appropriate for the client's pain management. Additionally, nalbuphine has mixed agonist-antagonist properties and can precipitate withdrawal symptoms in clients who are physically dependent on full opioid agonists like morphine. Due to these potential interactions and safety concerns, it is essential for the nurse to obtain clarification from the provider before administering nalbuphine to the client receiving morphine via a PCA pump.

A) Ondansetron: Ondansetron is an antiemetic medication commonly prescribed to manage nausea and vomiting, which can be side effects of opioid analgesics like morphine. There are no significant contraindications or interactions between ondansetron and morphine, making it a suitable choice for adjunctive therapy in clients receiving PCA morphine for cancer pain.

C) Insulin glargine: Insulin glargine is a long-acting insulin analog used to control blood glucose levels in clients with diabetes mellitus. While clients with cancer may have comorbidities such as diabetes, the prescription for insulin glargine is unlikely to require clarification in the context of concurrent morphine use. However, the nurse should verify the client's current blood glucose levels and adjust the insulin dosage as needed based on the client's glycemic control.

D) Acetaminophen: Acetaminophen is a non-opioid analgesic commonly used to manage mild to moderate pain. When used in combination with opioids like morphine, acetaminophen can provide additive pain relief and may reduce the total opioid dosage required. There are no significant contraindications or interactions between acetaminophen and morphine, making it a suitable choice for adjunctive pain management in clients receiving PCA morphine for cancer pain.

D) Calcium: Calcium supplements can interfere with the absorption of levothyroxine when taken concurrently. Levothyroxine absorption can be significantly reduced if taken with calcium-containing supplements or foods high in calcium. Therefore, clients should wait at least 4 hours after taking levothyroxine before consuming calcium supplements to ensure optimal absorption of the thyroid medication.

A) Zinc: Zinc supplements do not significantly interfere with the absorption of levothyroxine. While zinc can bind to levothyroxine and potentially decrease its absorption, the effect is minimal compared to calcium. However, it is generally recommended to take zinc supplements at least 4 hours apart from levothyroxine to avoid any potential interaction.

B) Vitamin C: Vitamin C supplements do not interfere with the absorption of levothyroxine and can be taken concurrently without significant interactions. There is no need for clients to wait a specific amount of time between taking levothyroxine and vitamin C supplements.

C) Ginkgo biloba: Ginkgo biloba supplements have not been shown to have a significant impact on the absorption of levothyroxine. However, given the variability in individual responses to supplements, it is still prudent to separate the administration of levothyroxine and ginkgo biloba by at least 4 hours to minimize any potential interactions.